tiprankstipranks
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
US Market
KPTI
Karyopharm Therapeutics
RESEARCH TOOLSreports
Want to see KPTI full AI Analyst Report?

Karyopharm Therapeutics (KPTI) Stock Forecast & Price Target

1,232 Followers
See the Price Targets and Ratings of:

KPTI Analyst Ratings

Strong Buy
7Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Karyopharm
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KPTI Stock 12 Month Forecast

Average Price Target

$15.83
▲(83.89% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Karyopharm Therapeutics in the last 3 months. The average price target is $15.83 with a high forecast of $28.00 and a low forecast of $7.00. The average price target represents a 83.89% change from the last price of $8.61.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","29":"$29","8.75":"$8.75","15.5":"$15.5","22.25":"$22.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.833333333333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8.75,15.5,22.25,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.77,10.249230769230769,11.728461538461538,13.207692307692309,14.686923076923076,16.166153846153847,17.645384615384614,19.124615384615385,20.603846153846156,22.083076923076923,23.56230769230769,25.04153846153846,26.520769230769233,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.77,9.313333333333333,9.856666666666666,10.4,10.943333333333333,11.486666666666666,12.030000000000001,12.573333333333334,13.116666666666667,13.66,14.203333333333333,14.746666666666668,15.290000000000001,{"y":15.833333333333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.77,8.633846153846154,8.497692307692308,8.361538461538462,8.225384615384614,8.089230769230769,7.953076923076923,7.816923076923077,7.680769230769231,7.544615384615384,7.408461538461538,7.272307692307692,7.136153846153846,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.76,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.78,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.31,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.59,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.82,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.77,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$28.00Average Price Target$15.83Lowest Price Target$7.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on KPTI
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$5→$7
Hold
-18.70%
Downside
Reiterated
05/15/26
Leerink Partners Sticks to Its Hold Rating for Karyopharm Therapeutics (KPTI)
RBC Capital Analyst forecast on KPTI
Brian Abrahams
RBC Capital
RBC Capital
$16
Buy
85.83%
Upside
Reiterated
05/14/26
RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)
H.C. Wainwright Analyst forecast on KPTI
Robert Burns
H.C. Wainwright
H.C. Wainwright
$8→$13
Buy
50.99%
Upside
Reiterated
05/06/26
Karyopharm price target raised to $13 from $8 at H.C. WainwrightKaryopharm price target raised to $13 from $8 at H.C. Wainwright
Piper Sandler Analyst forecast on KPTI
Edward Tenthoff
Piper Sandler
Piper Sandler
$8→$16
Buy
85.83%
Upside
Assigned
04/27/26
Karyopharm price target raised to $16 from $8 at Piper SandlerKaryopharm price target raised to $16 from $8 at Piper Sandler
Robert W. Baird Analyst forecast on KPTI
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
$21→$15
Buy
74.22%
Upside
Reiterated
03/25/26
Karyopharm price target lowered to $15 from $21 at BairdKaryopharm price target lowered to $15 from $21 at Baird
Rodman & Renshaw Analyst forecast on KPTI
Michael King
Rodman & Renshaw
Rodman & Renshaw
$28
Buy
225.20%
Upside
Initiated
03/09/26
Karyopharm initiated with a Buy at Rodman & RenshawKaryopharm initiated with a Buy at Rodman & Renshaw
Cantor Fitzgerald Analyst forecast on KPTI
Yanni Souroutzidis
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
03/06/26
Analysts' Top Healthcare Picks: Citius Oncology (CTOR), Karyopharm Therapeutics (KPTI)
Barclays Analyst forecast on KPTI
Peter Lawson
Barclays
Barclays
$10
Buy
16.14%
Upside
Reiterated
11/04/25
Barclays Remains a Buy on Karyopharm Therapeutics (KPTI)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on KPTI
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$5→$7
Hold
-18.70%
Downside
Reiterated
05/15/26
Leerink Partners Sticks to Its Hold Rating for Karyopharm Therapeutics (KPTI)
RBC Capital Analyst forecast on KPTI
Brian Abrahams
RBC Capital
RBC Capital
$16
Buy
85.83%
Upside
Reiterated
05/14/26
RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)
H.C. Wainwright Analyst forecast on KPTI
Robert Burns
H.C. Wainwright
H.C. Wainwright
$8→$13
Buy
50.99%
Upside
Reiterated
05/06/26
Karyopharm price target raised to $13 from $8 at H.C. WainwrightKaryopharm price target raised to $13 from $8 at H.C. Wainwright
Piper Sandler Analyst forecast on KPTI
Edward Tenthoff
Piper Sandler
Piper Sandler
$8→$16
Buy
85.83%
Upside
Assigned
04/27/26
Karyopharm price target raised to $16 from $8 at Piper SandlerKaryopharm price target raised to $16 from $8 at Piper Sandler
Robert W. Baird Analyst forecast on KPTI
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
$21→$15
Buy
74.22%
Upside
Reiterated
03/25/26
Karyopharm price target lowered to $15 from $21 at BairdKaryopharm price target lowered to $15 from $21 at Baird
Rodman & Renshaw Analyst forecast on KPTI
Michael King
Rodman & Renshaw
Rodman & Renshaw
$28
Buy
225.20%
Upside
Initiated
03/09/26
Karyopharm initiated with a Buy at Rodman & RenshawKaryopharm initiated with a Buy at Rodman & Renshaw
Cantor Fitzgerald Analyst forecast on KPTI
Yanni Souroutzidis
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
03/06/26
Analysts' Top Healthcare Picks: Citius Oncology (CTOR), Karyopharm Therapeutics (KPTI)
Barclays Analyst forecast on KPTI
Peter Lawson
Barclays
Barclays
$10
Buy
16.14%
Upside
Reiterated
11/04/25
Barclays Remains a Buy on Karyopharm Therapeutics (KPTI)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Karyopharm Therapeutics

3 Months
Peter LawsonBarclays
Success Rate
7/19 ratings generated profit
37%
Average Return
-12.28%
Copying Peter Lawson's trades and holding each position for 3 Months would result in 36.84% of your transactions generating a profit, with an average return of -12.28% per trade.
1 Year
Brian AbrahamsRBC Capital
Success Rate
9/31 ratings generated profit
29%
Average Return
-21.67%
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 29.03% of your transactions generating a profit, with an average return of -21.67% per trade.
2 Years
Brian AbrahamsRBC Capital
Success Rate
7/31 ratings generated profit
23%
Average Return
-27.53%
Copying Brian Abrahams's trades and holding each position for 2 Years would result in 22.58% of your transactions generating a profit, with an average return of -27.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KPTI Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
8
7
11
9
8
Buy
0
3
4
4
2
Hold
0
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
10
15
13
11
In the current month, KPTI has received 10 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. KPTI average Analyst price target in the past 3 months is 15.83.
Each month's total comprises the sum of three months' worth of ratings.

KPTI Financial Forecast

KPTI Earnings Forecast

Next quarter’s earnings estimate for KPTI is -$1.31 with a range of -$1.83 to -$0.81. The previous quarter’s EPS was -$1.24. KPTI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year KPTI has Performed in-line its overall industry.
Next quarter’s earnings estimate for KPTI is -$1.31 with a range of -$1.83 to -$0.81. The previous quarter’s EPS was -$1.24. KPTI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year KPTI has Performed in-line its overall industry.

KPTI Sales Forecast

Next quarter’s sales forecast for KPTI is $33.11M with a range of $29.90M to $39.10M. The previous quarter’s sales results were $35.07M. KPTI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year KPTI has Performed in-line its overall industry.
Next quarter’s sales forecast for KPTI is $33.11M with a range of $29.90M to $39.10M. The previous quarter’s sales results were $35.07M. KPTI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year KPTI has Performed in-line its overall industry.

KPTI Stock Forecast FAQ

What is KPTI’s average 12-month price target, according to analysts?
Based on analyst ratings, Karyopharm Therapeutics’s 12-month average price target is 15.83.
    What is KPTI’s upside potential, based on the analysts’ average price target?
    Karyopharm Therapeutics has 83.89% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is KPTI a Buy, Sell or Hold?
          Karyopharm Therapeutics has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Karyopharm Therapeutics’s price target?
            The average price target for Karyopharm Therapeutics is 15.83. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $28.00 ,the lowest forecast is $7.00. The average price target represents 83.89% Increase from the current price of $8.61.
              What do analysts say about Karyopharm Therapeutics?
              Karyopharm Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of KPTI?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.